Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of ARQ 197 in Patients With Microphthalmia Transcription Factor Associated Tumors

NCT00557609 is registered in ClinicalTrials.gov with ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) as lead sponsor.

NCT NCT00557609
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00557609 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of ARQ 197 in Patients With Microphthalmia Transcription Factor Associated Tumors
Lead sponsor
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2007
Completion date
February 28, 2011
Enrollment
47 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

alveolar soft part sarcoma (asps), clear cell sarcoma (ccs), renal cell carcinoma (rcc)